Submission of Monitoring Agency Report issued by ICRA Limited for the quarter ended December 31, 2025.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare Solutions has filed the quarterly Monitoring Agency Report from ICRA Limited for the quarter ended December 31, 2025, covering the use of its IPO proceeds raised in February 2024. The original net proceeds were INR 951.20 crores, later revised upward to INR 954.80 crores because issue-related expenses came in INR 3.60 crores lower than estimated. ICRA confirmed there is no material deviation from the disclosed objects of the issue. Of the four planned uses, loan repayment (Rs. 142.50 cr) is fully completed, long-term working capital funding (Rs. 480 cr) is ongoing, inorganic acquisitions (Rs. 237 cr) have slipped past the original September 30, 2025 target, and general corporate purposes (revised to Rs. 95.30 cr) have been fully deployed across items like NCD redemption, salaries, rent, and insurance.
This is a routine SEBI-mandated compliance filing that reassures shareholders the company is using IPO funds as promised, with no diversions. The slippage in the acquisition timeline is worth noting as it could delay inorganic growth benefits, but the overall picture is one of disciplined deployment with no negative findings from the monitoring agency.